Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mauro Ragonese

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Urologia|July 16, 2013
[Innovative treatments of non muscle invasive bladder cancer]Marco Racioppi, Daniele D'Agostino, Dario Pugliese, et al.
IJU Case Reports|November 9, 2020
Immediate ileal ureter replacement for ureteral avulsion during ureterescopyMauro Ragonese, Nazario Foschi, Francesco Pinto, et al.
International Journal of Legal Medicine|December 23, 2016
The periprostatic venous plexus: an unusual source of fatal pulmonary embolism during corporoplastyNazario Foschi, Mauro Ragonese, Vincenzo M Grassi, et al.
Journal of Geriatric Oncology|April 21, 2018
The challenges of Bacillus of Calmette-Guerin (BCG) therapy for high risk non muscle invasive bladder cancer treatment in older patientsMarco Racioppi, Luca Di Gianfrancesco, Mauro Ragonese, et al.
European Urology Oncology|August 15, 2019
Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder CancerMarco Racioppi, Luca Di Gianfrancesco, Mauro Ragonese, et al.
Clinical Genitourinary Cancer|December 14, 2020
Second-Line Conservative Device-Assisted Intravesical Treatment in Selected Patients With Recurrent High-Risk Non-Muscle-Invasive Bladder CancerLuca Di Gianfrancesco, Mauro Ragonese, Giuseppe Palermo, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology|February 21, 2019
Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?Marco Racioppi, Luca Di Gianfrancesco, Mauro Ragonese, et al.
BMC Cancer|December 8, 2018
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomesMarco Racioppi, Luca Di Gianfrancesco, Mauro Ragonese, et al.
Cureus|July 24, 2025
A Rare Case of Atypical Haemolytic Syndrome Following Right Retrograde Intrarenal Surgery (RIRS)Antonio Cretì, Francesco Pinto, Maria Chiara Sighinolfi, et al.
Current Urology|October 7, 2022
How to reduce bacillus Calmette-Guérin discontinuation in patients with severe functional impairmentLuca Di Gianfrancesco, Mauro Ragonese, Massimiliano Foti, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Urologia|July 16, 2013
[Innovative treatments of non muscle invasive bladder cancer]Marco Racioppi, Daniele D'Agostino, Dario Pugliese, et al.
IJU Case Reports|November 9, 2020
Immediate ileal ureter replacement for ureteral avulsion during ureterescopyMauro Ragonese, Nazario Foschi, Francesco Pinto, et al.
International Journal of Legal Medicine|December 23, 2016
The periprostatic venous plexus: an unusual source of fatal pulmonary embolism during corporoplastyNazario Foschi, Mauro Ragonese, Vincenzo M Grassi, et al.
Journal of Geriatric Oncology|April 21, 2018
The challenges of Bacillus of Calmette-Guerin (BCG) therapy for high risk non muscle invasive bladder cancer treatment in older patientsMarco Racioppi, Luca Di Gianfrancesco, Mauro Ragonese, et al.
European Urology Oncology|August 15, 2019
Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder CancerMarco Racioppi, Luca Di Gianfrancesco, Mauro Ragonese, et al.
Clinical Genitourinary Cancer|December 14, 2020
Second-Line Conservative Device-Assisted Intravesical Treatment in Selected Patients With Recurrent High-Risk Non-Muscle-Invasive Bladder CancerLuca Di Gianfrancesco, Mauro Ragonese, Giuseppe Palermo, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology|February 21, 2019
Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?Marco Racioppi, Luca Di Gianfrancesco, Mauro Ragonese, et al.
BMC Cancer|December 8, 2018
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomesMarco Racioppi, Luca Di Gianfrancesco, Mauro Ragonese, et al.
Cureus|July 24, 2025
A Rare Case of Atypical Haemolytic Syndrome Following Right Retrograde Intrarenal Surgery (RIRS)Antonio Cretì, Francesco Pinto, Maria Chiara Sighinolfi, et al.
Current Urology|October 7, 2022
How to reduce bacillus Calmette-Guérin discontinuation in patients with severe functional impairmentLuca Di Gianfrancesco, Mauro Ragonese, Massimiliano Foti, et al.
Pageof 9